Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinder Invest in connection with an investment in Stureplansgruppen
Mandate

Vinge advises Cinder Invest in connection with an investment in Stureplansgruppen

March 19, 2021 Environmental Law M&A

Vinge is advising Cinder Invest in connection with their investment in Stureplansgruppen. The investment provides Stureplansgruppen with the preconditions to overcome the pandemic, to develop existing operations and to continue to create new guest experiences. Cinder Invest will own 20 per cent.

Cinder Invest is a joint venture between AFA, AMF, FAM together with the Wallenberg Foundations, the Fourth Swedish National Pension Fund and SEB. Cinder Invest will invest in viable Swedish companies in order to help them to overcome the adverse economic consequences of Covid-19.

Vinge's team primarily consisted of, among others, Johan Larsson, Ellinor Wargenbrant, Niclas Winnberg and Amanda Steen.

 

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026